Eli Lilly Launches Platform to Expand Employer Coverage of Obesity Drugs

In a major move to bridge the gap in healthcare access, Eli Lilly and Company announced the launch of its "Employer Connect" platform. This new initiative is specifically designed to tackle a primary barrier to patient care by helping companies provide flexible, transparent, and affordable weight-loss medication benefits to their workforces.

Currently, the high list prices of obesity and diabetes treatments like Zepbound and Mounjaro—which regularly top $1,000 per month—serve as a massive financial hurdle. Due to these high costs, employer coverage remains uneven, leaving approximately half of all individuals with commercial insurance unable to access or maintain these necessary treatments. This coverage gap has profound economic implications; obesity affects over 100 million American adults and costs the U.S. economy an estimated $1.7 trillion annually in direct medical costs and lost productivity.

To combat this, the Employer Connect platform allows employers to bypass traditional, restrictive benefit designs. Through the program, companies can provide the multi-dose Zepbound KwikPen for a flat, discounted net price of $449 per month across all doses. Importantly, this arrangement avoids complex rebate systems, giving employers clear visibility into pricing so they can accurately determine if they can afford to offer the drug.

The platform connects employers directly with more than 15 independent third-party program administrators, including well-known health entities like GoodRx, Mark Cuban's Cost Plus Drug Co., Teladoc Health, and Sesame. Because all administrators on the platform offer the medication at the exact same discounted rate, they compete purely on the value and quality of their services.

This gives employers the ultimate flexibility to choose administrators that best fit their specific budget and workforce needs. Solutions range from basic benefits administration—handling enrollment, eligibility, and claims—to comprehensive obesity management programs that feature telehealth, lifestyle support, and nutritional counseling.

By increasing price transparency and offering customizable benefit structures, Eli Lilly aims to address the "core tensions" companies face when evaluating health benefits. The pharmaceutical giant hopes this straightforward approach will encourage employers who have been "sitting on the sidelines" to finally opt into obesity coverage for their workers. Ultimately, the Employer Connect initiative seeks to broaden employee access to highly sought-after medications at low out-of-pocket costs, while keeping corporate healthcare expenses strictly within budget.

---

🔖 Sources

Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.

Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients

---

Keywords: Employer Coverage of Obesity Drugs

Employer Coverage of Obesity Drugs

---